CDH
VRTX icon

Charles D. Hyman’s Vertex Pharmaceuticals VRTX Stock Holding History

Charles D. Hyman’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$375K Hold
800
– – 0.02% 184
2024
Q1 		$334K Hold
800
– – 0.02% 199
2023
Q4 		$326K Hold
800
– – 0.02% 199
2023
Q3 		$278K Hold
800
– – 0.02% 198
2023
Q2 		$282K Hold
800
– – 0.02% 205
2023
Q1 		$252K Hold
800
– – 0.02% 215
2022
Q4 		$231K Hold
800
– – 0.02% 219
2022
Q3 		$232K Hold
800
– – 0.02% 210
2022
Q2 		$225K Buy
+800
New +$214K 0.02% 219

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Charles D. Hyman's VRTX Position: Q2 2024 in Review

Charles D. Hyman held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2024 at 800 shares worth $375K. The position accounts for 0.02% of the portfolio, ranked #184.

Charles D. Hyman first reported a position in VRTX in Q2 2022 and has held it in 9 quarters since. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Charles D. Hyman held 800 shares of Vertex Pharmaceuticals worth $375K as of Q2 2024.
  • Charles D. Hyman left its Vertex Pharmaceuticals share count unchanged in Q2 2024.
  • Vertex Pharmaceuticals made up 0.02% of Charles D. Hyman's portfolio in Q2 2024, its #184 holding.
  • Charles D. Hyman first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 9 quarters since.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Charles D. Hyman's 13F filing for Q2 2024, filed 25 Jul 2024.